LLY

Business Context and Reporting Period

This summary covers the Form 10-Q filed by Eli Lilly & Co for the quarter ended March 31, 2004. The company operates primarily in the pharmaceutical products segment, with animal health operations included in this segment for reporting purposes. As of April 20, 2004, there were 1,129,485,533 shares of common stock outstanding.

Key Financial Metrics

Note: Total debt calculated as Short-term borrowings ($807.1M) + Long-term debt ($4,503.6M) for Q1 2004.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 17% year-over-year, driven by growth in major products (Zyprexa, Gemzar, Evista) and newer launches (Alimta, Cialis, Forteo). International sales grew 24%, while U.S. sales grew 12%.
• Profitability: Despite a 25% increase in income before taxes, net income decreased slightly (2%) due to a higher effective tax rate (34.9% vs. 17.6%). The tax rate increase was primarily caused by the non-deductibility of a $362.3 million charge for acquired in-process research and development (IPR&D) from the Applied Molecular Evolution (AME) acquisition.
• Acquisition Impact: The AME acquisition resulted in a $362.3 million charge to income, reducing earnings per share by $0.33. This charge is not tax-deductible.
• Expense Trends: Research and development expenses rose 22% to $646.6 million, and marketing/administrative expenses rose 16% to $1.06 billion, reflecting increased clinical trial costs and support for new product launches.
• Debt Levels: Total debt increased by $426.4 million from the prior year-end, primarily due to the issuance of commercial paper.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• 2004 EPS Guidance: Management expects full-year 2004 diluted earnings per share to be in the range of $2.47 to $2.52, excluding future unusual items. This includes the $0.33 per-share impact of the Q1 IPR&D charge.
• Q2 2004 EPS Guidance: Expected to be in the range of $0.67 to $0.69, excluding unusual items.
• Sales Growth: Full-year 2004 sales growth is expected to be in the low double digits.
• Product Pipeline: Key upcoming launches include Cymbalta (depression) in the summer of 2004 and Evista in Japan in Q2 2004. Zyprexa IntraMuscular was launched in April 2004.

Risks and Contingencies

• Zyprexa Patent Litigation: Three generic manufacturers (Zenith, Reddy, Teva) have challenged Zyprexa patents. A trial was held in early 2004, with a ruling expected in summer 2004. An unfavorable outcome could materially adversely impact operations and liquidity.
• Government Investigations: The U.S. Attorney for the Eastern District of Pennsylvania commenced a civil investigation in March 2004 regarding marketing and promotional practices for Prozac and Zyprexa. Additionally, a grand jury investigation regarding Evista marketing practices is ongoing.
• Product Liability: The company faces numerous lawsuits regarding Zyprexa (diabetes/high blood glucose claims), DES, and thimerosal. Accruals for estimated exposures are recorded, but outcomes remain uncertain.
• Evista Patent Litigation: Barr Laboratories has challenged Evista patents, with a trial proposed for August 2005.

Investor Verification Checklist

• Patent Litigation Status: Monitor the summer 2004 ruling on the Zyprexa patent challenges, as a loss could trigger generic competition and significant revenue decline.
• Regulatory Investigations: Track the outcome of the DOJ and U.S. Attorney investigations into marketing practices for potential fines or penalties.
• Product Launch Execution: Verify sales performance of new launches (Cymbalta, Zyprexa IntraMuscular, Alimta) against management's low double-digit growth guidance.
• Tax Rate Normalization: Confirm if the effective tax rate returns to the expected ~22% for the remainder of 2004 as projected by management.
• Debt Management: Review future debt issuances planned to fund operating needs and capital expenditures, given the increase in short-term borrowings.